Prolactin-releasing peptide: a new tool for obesity treatment

0463385 - ÚOCHB 2017 RIV GB eng J - Článek v odborném periodiku
Kuneš, Jaroslav - Pražienková, Veronika - Popelová, Andrea - Mikulášková, Barbora - Zemenová, Jana - Maletínská, Lenka
Prolactin-releasing peptide: a new tool for obesity treatment.
Journal of Endocrinology. Roč. 230, č. 2 (2016), R51-R58. ISSN 0022-0795. E-ISSN 1479-6805
Grant CEP: GA ČR(CZ) GA15-08679S
Institucionální podpora: RVO:61388963
Klíčová slova: prolactin-releasing peptide * lipidization * obesity * GPR10 * anorexigenic * mice
Kód oboru RIV: FB - Endokrinologie, diabetologie, metabolizmus, výživa
Impakt faktor: 4.706, rok: 2016

Obesity is an escalating epidemic, but an effective noninvasive therapy is still scarce. For obesity treatment, anorexigenic neuropeptides are promising tools, but their delivery from the periphery to the brain is complicated because peptides have a low stability and limited ability to cross the blood-brain barrier. In this review, we summarize results of several studies with our newly designed lipidized analogs of prolactin-releasing peptide (PrRP). PrRP is involved in feeding and energy balance regulation as demonstrated by obesity phenotypes of both PrRP-and PrRP-receptor-knockout mice. Lipidized PrRP analogs showed binding affinity and signaling in PrRP receptor-expressing cells similar to natural PrRP. Moreover, these analogs showed high binding affinity also to anorexigenic neuropeptide FF (NPFF)-2 receptor. Acute peripheral administration of myristoylated and palmitoylated PrRP analogs to mice and rats induced strong and long-lasting anorexigenic effects and neuronal activation in the brain areas involved in food intake regulation. Two-week-long subcutaneous administration of palmitoylated PrRP31 and myristoylated PrRP20 lowered food intake, body weight, improved metabolic parameters and attenuated lipogenesis in mice with diet-induced obesity. A strong anorexigenic, body weight-reducing and glucose tolerance-improving effect of palmitoylated-PrRP31 was shown also in diet-induced obese rats after its repeated 2-week-long peripheral administration. Thus, the strong anorexigenic and body weight-reducing effects of palmitoylated PrRP31 and myristoylated PrRP20 make these analogs attractive candidates for antiobesity treatment. Moreover, PrRP receptor might be a new target for obesity therapy.
Trvalý link: http://hdl.handle.net/11104/0262599